For research use only. Not for therapeutic Use.
Ascrinvacumab (PF-03446962) is a human IgG2 monoclonal antibody targets ALK-1. Ascrinvacumab shows binding efficiency with human ALK1 with a Kd value of 7 nM. Ascrinvacumab can be used for the research of hepatocellular carcinoma (HCC)[1].
Ascrinvacumab binds to cellular human ALK1 with a Kd value of 7 nm[1].
Ascrinvacumab (30 min) blocks bone morphogenetic protein 9 (BMP9)- and fetal calf serum (FCS)-induced responses and mitigates BMP9-induced intensity and duration of Smad1 phosphorylation[1].
Ascrinvacumab (0.01-10 μg/mL; 2 h) inhibits BMP9 binding to ALK1[1].
Ascrinvacumab (40 μg/mL; 2 h) potently inhibits endothelial sprouting in human umbilical vein endothelial cells (HUVECs)[1].
Ascrinvacumab decreases human vessel density and improves antitumor efficacy when combined with bevacizumab (anti-VEGF) in mouse chimera tumor model[1].
| Catalog Number | I042238 |
| CAS Number | 1463459-96-2 |
| Purity | ≥95% |
| Reference | [1]. van Meeteren LA, et al. Anti-human activin receptor-like kinase 1 (ALK1) antibody attenuates bone morphogenetic protein 9 (BMP9)-induced ALK1 signaling and interferes with endothelial cell sprouting. J Biol Chem. 2012 May 25;287(22):18551-61. |
